AbbVie has filed for approval of its therapy for Parkinson's disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current drugs that often fail to ...

AbbVie has reported that a subcutaneous infusion of Parkinson's disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving the way for regulatory filings.

In June 2024, the FDA issued a complete response letter for the new drug application of ABBV-951. "FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment" was originally created and ...

AbbVie has also faced its share of pipeline setbacks. Its Parkinson’s candidate, ABBV-951, has hit a roadblock, having faced the FDA’s rejection twice. Accretive Acquisitions: AbbVie has been ...